The complement system, a key component of innate immunity, exerts profound influence on the initiation, progression and destabilisation of atherosclerotic plaques. Activation may proceed via the ...

Recent clinical trials utilizing high doses of adeno-associated virus (AAV) vectors have highlighted a new challenge to AAV gene transfer—activation of the complement system. A new article in Human ...

K. pneumoniae is frequently the source of hospital-acquired infections and, due to the widespread use of antibiotics in these settings, has also acquired numerous resistance genes. In fact, over ...

Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...